[HTML][HTML] Bempedoic acid: for whom and when
Abstract Purpose of Review The aim of creating an orally active non-statin cholesterol-
lowering drug was achieved with bempedoic acid, a small linear molecule providing both a …
lowering drug was achieved with bempedoic acid, a small linear molecule providing both a …
Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events
E Raschi, M Casula, AFG Cicero, A Corsini… - Pharmacology & …, 2023 - Elsevier
The pharmacological treatment of dyslipidemia, a major modifiable risk factor for developing
atherosclerotic cardiovascular disease (ASCVD), remains a debated and controversial …
atherosclerotic cardiovascular disease (ASCVD), remains a debated and controversial …
Metabolic syndrome—A new definition and management guidelines
P Dobrowolski, A Prejbisz, A Kuryłowicz… - Arterial …, 2022 - journals.viamedica.pl
The joint position paper by Polish Society of Hypertension, Polish Society for the Treatment
of Obesity, Polish Lipid Association, Polish Association for Study of Liver, Polish Society of …
of Obesity, Polish Lipid Association, Polish Association for Study of Liver, Polish Society of …
The association between daily step count and all-cause and cardiovascular mortality: a meta-analysis
Aims There is good evidence showing that inactivity and walking minimal steps/day increase
the risk of cardiovascular (CV) disease and general ill-health. The optimal number of steps …
the risk of cardiovascular (CV) disease and general ill-health. The optimal number of steps …
Step‐by‐step diagnosis and management of the nocebo/drucebo effect in statin‐associated muscle symptoms patients: a position paper from the International Lipid …
PE Penson, E Bruckert, D Marais… - Journal of cachexia …, 2022 - Wiley Online Library
Statin intolerance is a clinical syndrome whereby adverse effects (AEs) associated with
statin therapy [most commonly statin‐associated muscle symptoms (SAMS)] result in the …
statin therapy [most commonly statin‐associated muscle symptoms (SAMS)] result in the …
[HTML][HTML] Coffee or tea: Anti-inflammatory properties in the context of atherosclerotic cardiovascular disease prevention
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of premature death
worldwide. Inflammation and its biomarkers, like C-reactive protein (CRP), among the risk …
worldwide. Inflammation and its biomarkers, like C-reactive protein (CRP), among the risk …
[HTML][HTML] A network meta-analysis on the comparative effect of nutraceuticals on lipid profile in adults
It is estimated that 2.6 million deaths worldwide can be attributed to hypercholesterolemia.
The main reason for non-adherence to statin therapy are the statin-associated muscle …
The main reason for non-adherence to statin therapy are the statin-associated muscle …
[HTML][HTML] Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP)
Cardiovascular disease (CVD) is a chronic non-communicable disease (NCD) and the
predominant cause of morbidity and mortality worldwide. Substantial reductions in the CVD …
predominant cause of morbidity and mortality worldwide. Substantial reductions in the CVD …
[HTML][HTML] Red yeast rice for dyslipidaemias and cardiovascular risk reduction: A position paper of the International Lipid Expert Panel
The risk of atherosclerotic cardiovascular disease (ASCVD) is strongly related to lifetime
exposure to low-density lipoprotein (LDL)-cholesterol in longitudinal studies. Lipid-lowering …
exposure to low-density lipoprotein (LDL)-cholesterol in longitudinal studies. Lipid-lowering …
[HTML][HTML] Targeted treatment against lipoprotein (a): the coming breakthrough in lipid lowering therapy
Atherosclerotic cardiovascular diseases (ASCVD) are a very important cause of premature
death. The most important risk factor for ASCVD is lipid disorders. The incidence of lipid …
death. The most important risk factor for ASCVD is lipid disorders. The incidence of lipid …